Jonathan A Fallowfield
Overview
Explore the profile of Jonathan A Fallowfield including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
2594
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Brennan P, Tavabie O, Li W, Marjot T, Corless L, Fallowfield J, et al.
Lancet Gastroenterol Hepatol
. 2024 Mar;
9(6):577-582.
PMID: 38428439
The American, European, and Latin American liver societies have proposed a change in the nomenclature we use to describe alcohol-related liver disease and non-alcoholic fatty liver disease. Additionally, a term...
12.
Perry A, Hadad N, Chatterjee E, Ramos M, Farber-Eger E, Roshani R, et al.
medRxiv
. 2024 Feb;
PMID: 38352394
Metabolic dysfunction-associated steatotic liver disease (MASLD) prevalence is increasing in parallel with an obesity pandemic, calling for novel strategies for prevention and treatment. We defined a circulating proteome of human...
13.
Ramos M, Kendall T, Drozdov I, Fallowfield J
Ann Hepatol
. 2023 Dec;
29(2):101278.
PMID: 38135251
Metabolic dysfunction-associated steatotic liver disease (MASLD), defined by the presence of liver steatosis together with at least one out of five cardiometabolic factors, is the most common cause of chronic...
14.
Kendall T, Jimenez-Ramos M, Turner F, Ramachandran P, Minnier J, McColgan M, et al.
Nat Med
. 2023 Oct;
29(11):2939-2953.
PMID: 37903863
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the commonest cause of chronic liver disease worldwide and represents an unmet precision medicine challenge. We established a retrospective national cohort of 940...
15.
Morgan K, Morley S, Raja A, Vandeputte M, Samuel K, Waterfall M, et al.
J Clin Med
. 2023 Jun;
12(12).
PMID: 37373688
The gut-liver axis is defined by dietary and environmental communication between the gut, microbiome and the liver with its redox and immune systems, the overactivation of which can lead to...
16.
Brennan P, Elsharkawy A, Kendall T, Loomba R, Mann D, Fallowfield J
Nat Rev Gastroenterol Hepatol
. 2023 Jun;
20(10):679-688.
PMID: 37268740
Nonalcoholic steatohepatitis (NASH) might soon become the leading cause of end-stage liver disease and indication for liver transplantation worldwide. Fibrosis severity is the only histological predictor of liver-related morbidity and...
17.
Carlessi R, Denisenko E, Boslem E, Kohn-Gaone J, Main N, Abu Bakar N, et al.
Cell Genom
. 2023 May;
3(5):100301.
PMID: 37228755
Current approaches to staging chronic liver diseases have limited utility for predicting liver cancer risk. Here, we employed single-nucleus RNA sequencing (snRNA-seq) to characterize the cellular microenvironment of healthy and...
18.
Fairfield C, Drake T, Pius R, Bretherick A, Campbell A, Clark D, et al.
Hepatology
. 2021 Oct;
75(5):1081-1094.
PMID: 34651315
Background And Aims: Genome-wide association studies (GWAS) have identified several risk loci for gallstone disease. As with most polygenic traits, it is likely that many genetic determinants are undiscovered. The...
19.
Grecian S, McLachlan S, Fallowfield J, Hayes P, Guha I, Morling J, et al.
Obes Sci Pract
. 2021 Oct;
7(5):497-508.
PMID: 34631129
Background: Type 2 diabetes (T2D) is associated with increased risk of progression to cirrhosis and hepatocellular carcinoma (HCC) in people with chronic liver diseases, particularly non-alcoholic fatty liver disease (NAFLD)....
20.
Andersson A, Kelly M, Imajo K, Nakajima A, Fallowfield J, Hirschfield G, et al.
Clin Gastroenterol Hepatol
. 2021 Oct;
20(11):2451-2461.e3.
PMID: 34626833
Background & Aims: Nonalcoholic fatty liver disease (NAFLD) is increasing in prevalence worldwide. NAFLD is associated with excess risk of all-cause mortality, and its progression to nonalcoholic steatohepatitis (NASH) and...